Minerva Neurosciences logo

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Minerva Neurosciences to Report Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates on March 8, 2021
Management to host conference call WALTHAM, Mass. , March 01, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
View HTML
PDF Version
Toggle Summary Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023
Management to Host Conference Call BURLINGTON, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc.  (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will
View HTML
PDF Version
Toggle Summary Minerva Neurosciences to Report Second Quarter 2015 Financial Results and Host Conference Call on August 5, 2015 View HTML
Toggle Summary Minerva Neurosciences to Report Second Quarter 2016 Financial Results and Business Updates on August 4, 2016 View HTML
Toggle Summary Minerva Neurosciences to Report Second Quarter 2017 Financial Results and Business Updates on August 3, 2017
WALTHAM, Mass. , July 27, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business
View HTML
Toggle Summary Minerva Neurosciences to Report Second Quarter 2018 Financial Results and Business Updates on August 2, 2018
Management to host conference call WALTHAM, Mass. , July 26, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
View HTML
PDF Version
Toggle Summary Minerva Neurosciences to Report Second Quarter 2019 Financial Results and Business Updates on August 5, 2019
Management to host conference call WALTHAM, Mass. , July 29, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
View HTML
PDF Version
Toggle Summary Minerva Neurosciences to Report Second Quarter 2020 Financial Results and Business Updates on August 3, 2020
Management to host conference call WALTHAM, Mass. , July 27, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
View HTML
PDF Version
Toggle Summary Minerva Neurosciences to Report Second Quarter 2021 Financial Results and Business Updates on August 2, 2021
Management to host conference call WALTHAM, Mass. , July 26, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
View HTML
PDF Version
Toggle Summary Minerva Neurosciences to Report Third Quarter 2015 Financial Results and Host Conference Call on November 5, 2015 View HTML
Displaying 171 - 180 of 194 results